Maria Vittoria Dieci, MD, University of Padova, Padova, Italy, discusses the role of tumor-infiltrating lymphocytes (TILs) in patients with early human epidermal growth factor receptor 2 (HER2)-positive breast cancer who were enrolled in the ShortHER trial (NCT00629278). The analysis showed that a higher level of TILs was significantly associated with both distant disease-free survival and overall survival in multivariable models. The study also found that patients with high TILs had a significantly better outcome than patients with low TILs, regardless of the treatment arm. Finally, the data confirmed a significant interaction between TILs and the treatment arm, indicating that patients with low TILs benefit more from a longer duration of treatment, while patients with high TILs may benefit more from a shorter treatment duration. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
